List of works - Sabrina Arena

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

scientific article published on 12 December 2019

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

scientific article published on 8 December 2016

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

scientific article (publication date: 2012)

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

scientific article

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

scientific article

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

scientific article published in February 2014

Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer

scientific article published on 23 May 2018

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

scientific article published on 8 June 2017

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

scientific article

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

scientific article published on 19 May 2020

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

scientific article

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

scholarly article published in Targeted oncology

Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells

scientific article published on 01 August 2007

Expression and functional regulation of myoglobin in epithelial cancers

scientific article

Genetic targeting of the kinase activity of the Met receptor in cancer cells

scientific article

High-dose vitamin C enhances cancer immunotherapy

scientific article published on 01 February 2020

Identification of cancer genes by mutational profiling of tumor genomes

scientific article (publication date: 21 March 2005)

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

scientific article published on March 2010

Isogenic mutant human cells: a new tool for personalized cancer medicine

scientific article

Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers

scientific article

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

scientific article published on February 2016

Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.

scientific article

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

scientific article published on 16 June 2016

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells

scientific article

PIK3CA cancer mutations display gender and tissue specificity patterns

scientific article published in February 2008

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

scientific article published on 02 August 2019

Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges

scientific article published on 05 June 2021

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

scientific article

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

scientific article

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

scientific article published on 01 October 2020

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

scientific article published on 27 December 2013

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

scientific article

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.

scientific article

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

scientific article published on 10 June 2015

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

scientific article

Understanding how kinase-targeted therapies work

scientific article

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer

scientific article published on 14 March 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

scientific article

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells

scientific article published in February 2004

List of works by Sabrina Arena

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

Adaptive mutability of colorectal cancers in response to targeted therapies

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells

Expression and functional regulation of myoglobin in epithelial cancers

Genetic targeting of the kinase activity of the Met receptor in cancer cells

High-dose vitamin C enhances cancer immunotherapy

Identification of cancer genes by mutational profiling of tumor genomes

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Isogenic mutant human cells: a new tool for personalized cancer medicine

Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells

PIK3CA cancer mutations display gender and tissue specificity patterns

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

Understanding how kinase-targeted therapies work

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells